#Israel #Cancer Immunotherapy #Compugen #Holon #virtual conferences

Compugen to Engage with Investors Virtually in April 2025

Compugen Ltd., the clinical-stage cancer immunotherapy innovator based in Israel, will soon participate in multiple virtual investor conferences scheduled for April 2025. These events will showcase the company’s commitment to advancing cancer treatment through its cutting-edge computational target discovery platform.

Conference Schedule

The company announced its participation in three major investor conferences that will take place in April:

1. H.C. Wainwright 2nd Annual AI-Based Drug Discovery & Development Conference
Date: April 2, 2025
Format: Fireside chat and one-on-one meetings
Fireside Chat Time: 9:30 AM ET

2. 24th Annual Needham Virtual Healthcare Conference
Date: April 7, 2025
Format: Fireside chat and one-on-one meetings
Fireside Chat Time: 8:00 AM ET

3. Stifel's 2025 Virtual Targeted Oncology Forum
Date: April 9, 2025
Format: Fireside chat and one-on-one meetings
Fireside Chat Time: 12:00 PM ET

For those interested, live presentations can be accessed via Compugen's Investor Relations website, along with replays following the events.

About Compugen

Compugen has established a prominent position in the biopharmaceutical industry, driven by its innovative approach to drug discovery. Utilizing its proprietary Unigen TM platform, the company identifies novel drug targets and potential pathways for developing effective cancer immunotherapies. Currently, Compugen’s portfolio includes two promising product candidates undergoing Phase 1 development—COM701, a first-in-class anti-PVRIG antibody, and COM902, which targets TIGIT proteins to treat solid tumors.

Apart from these, the company also has a bispecific antibody, Rilvegostomig, which is in Phase 3 development by AstraZeneca, focusing on a dual-target approach using PD-1 and TIGIT components. Another antibody, GS-0321, under development for high affinity anti-IL-18 binding, is also in Phase 1 and licensed to Gilead.

Compugen’s early-stage immuno-oncology programs demonstrate its commitment to enhancing anti-cancer immunity, further solidifying its role as a pioneer in targeted cancer therapies. With headquarters in Israel and an office in San Francisco, Compugen continues to expand its global footprint and influence in the oncology space. The company's stocks are traded under the symbol CGEN on both the Nasdaq and the Tel Aviv Stock Exchange.

For additional information or media inquiries, Yvonne Naughton, Ph.D., serves as the Head of Investor Relations and Corporate Communications and can be reached at +1 (628) 241-0071 or through email at [email protected]

Conclusion

Compugen's active involvement in these virtual conferences showcases its dedication to transparency with investors and stakeholders while highlighting its advancements in the ever-evolving field of cancer immunotherapy. If you wish to keep abreast of the company’s progress, be sure to tune in to these pivotal discussions throughout April 2025.